Group 1 - The 2025 Biomanufacturing Industry Conference was held in Guangzhou, focusing on the development of the biomanufacturing industry and gathering various stakeholders including government officials, industry experts, and investors [1][2] - The biomanufacturing industry is identified as a strategic emerging industry in China's 14th Five-Year Plan, with a target of reaching a total output value of approximately 500 billion yuan by 2027 and aiming for a trillion yuan scale by 2035 [2][3] - Guangzhou has established a dedicated working group for biomanufacturing development, aiming to create a competitive biomanufacturing industry cluster by 2027, focusing on five key areas: biomedicine, biomaterials, biological food, biomedicine, and biological agriculture [2][3] Group 2 - Huangpu District and Guangzhou Development Zone are positioned as the core areas for biomanufacturing, with a comprehensive policy support system established to facilitate the entire chain from R&D to industrialization [3][4] - The Guangzhou Frontier Biotechnology and Biomanufacturing Innovation Promotion Center was officially inaugurated, aiming to create a collaborative innovation platform involving government, industry, academia, and research institutions [4][5] - The conference featured various sessions on topics such as "Pharmaceutical Health and Beauty," "Agriculture, Food, and Materials Industry," and "Artificial Intelligence and Biomanufacturing Innovation," highlighting the innovative achievements of local enterprises [5][6] Group 3 - Local companies like Chuang'er Biotechnology and Muen Biotechnology showcased their innovative products, with Chuang'er receiving regulatory approval for its collagen product and Muen being recognized for its extensive microbial library [5][6] - Guangzhou aims to position biomanufacturing as a strategic pillar for high-quality urban development, attracting global biotech companies and top talent to foster innovation and create a globally influential biomanufacturing innovation hub [6]

Investment Rating - Industry Rating: Overweight [1] Core Views - The chemical sector showed a weekly performance ranking of 8th with a gain of 1.99%, outperforming the Shanghai Composite Index by 1.63 percentage points and the ChiNext Index by 5.85 percentage points [4][22]. - The chemical industry is expected to continue its differentiated trend in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4]. Summary by Sections Industry Performance - The chemical sector's overall performance for the week of October 9-10, 2025, was a gain of 1.99%, ranking 8th among sectors [22]. - The top three performing sub-sectors were phosphate and phosphorus chemicals (6.26%), titanium dioxide (4.23%), and oil and petrochemical trade (4.23%) [23]. Key Industry Dynamics - Synthetic biology is at a pivotal moment, with low-energy products expected to gain a longer growth window due to the adjustment of energy structures [4]. - The upcoming quota policy for third-generation refrigerants is anticipated to enter a high prosperity cycle, with demand expected to grow steadily due to market expansion in Southeast Asia [5]. - The electronic specialty gases market is characterized by high technical barriers and high added value, with significant opportunities for domestic substitution [6][8]. - The trend of light hydrocarbon chemicals is becoming global, with a shift towards lighter raw materials for olefin production [8]. - The COC polymer industry is accelerating its domestic industrialization process, driven by supply chain security concerns and the shift of downstream industries to domestic production [9]. - Potash fertilizer prices are expected to rebound as major producers reduce output and the demand for fertilizers increases due to rising grain prices [10]. - The MDI market is characterized by oligopoly, with a favorable supply structure expected as demand gradually recovers [12].

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and sustainable practices [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally, providing insights into regulatory frameworks that shape the industry [5]. - It highlights the importance of supportive policies in fostering innovation and growth within the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing key players and their roles [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The white paper lists the top 10 chain enterprises in China's biomanufacturing industry, showcasing leaders in the field [6]. - It also details the strategic directions of 15 publicly listed companies involved in synthetic biology, summarizing their development strategies [6]. Group 5: Investment and Challenges - An analysis of the investment landscape in synthetic biology from 2024 to mid-2025 is included, providing insights into funding trends and opportunities [6]. - The report discusses challenges faced by the biomanufacturing industry in China, along with targeted policy recommendations to address these issues [6].

/生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ 资本事件 | 美尚洁生物 【SynBioCon】 获 悉 ，近日，江苏美尚洁生物科技有限公司 （以下简称 "美尚洁生物"）宣布已 成功完成数千万人民币的新一轮 A+ 轮 融资。 本轮募集资金将用于进一步加速公司在基因工程合成生物领域的研发投入， 推动其重组人源化胶原 蛋白产品的临床转化与市场拓展，并持续优化其技术平台 ，计划在宜兴落地新的三类器械生产管线 。 此外， 本轮跟投还有数千万的跟投额度，其它数家投资机构仍在积极跟进中。 自2018年成立以来，美尚洁生物始终深耕于基因工程合成生物科技领域，尤其在 重组人源化胶原蛋 白产品的研发及医疗应用 方面取得了突破性进展。此次融资的成功，不仅是对我们现有成果和未来 潜力的肯定，更是对我们坚持技术创新的有力证明。我们将以此为契机，进一步加大研发力度，加快 产品上市步伐，为医疗健康领域带来更安全、更有效的解决方案。" 美尚洁生物的核心竞争力在于其创新性的技术平台。 作为 国内首家基于 AI 技术进行重组融合蛋白 研发 的公司， 已成功运用 AI模型技术完成了序列片段的多样 ...

Core Viewpoint - The article highlights the investment in Sichuan Yingjiaohesheng Technology Co., Ltd., a major producer of steviol glycosides, emphasizing its innovative approach using synthetic biology and its significant market potential in the sugar substitute industry [5][8]. Group 1: Company Overview - Yingjiaohesheng was established in 2015 and focuses on producing natural products using synthetic biology technology, with applications in pharmaceuticals, health supplements, and food and beverages [8]. - The company is recognized as one of the largest suppliers of steviol glycosides in China and has successfully entered the U.S. market since 2019, becoming part of the global supply chains of several international food and beverage companies [8][10]. - Yingjiaohesheng's product line includes coenzyme Q10, new steviol glycosides, β-nicotinamide mononucleotide (NMN), and vanillin, covering multiple sectors [8]. Group 2: Market and Technology - Steviol glycosides are a key component in many "zero-calorie" food and beverage products, with a caloric value only 1/300 that of sucrose, making them a popular sugar substitute [6][8]. - The company’s unique technology route—synthetic biology—offers significant cost advantages over traditional extraction methods, which have low yield and high waste [10]. - Synthetic biology allows for the production of steviol glycosides at a scale that can surpass traditional methods, with one fermentation tank yielding the equivalent of thousands of acres of stevia plants [10]. Group 3: Industry Context and Policy Support - The synthetic biology sector in China has seen increased investment and policy support, with total annual investments ranging from 50 to 100 billion RMB from 2018 to 2020, and a significant surge in 2021 [14][15]. - Chengdu, where Yingjiaohesheng is located, has strategically positioned itself as a hub for the biopharmaceutical industry, with a total scale of 350 billion RMB in the health industry as of 2023 [19][20]. - The city has implemented policies to foster the development of synthetic biology, aiming to create a robust ecosystem that integrates innovation, capital, and industry [21][22].

Core Viewpoint - The article emphasizes the critical role of new materials in driving technological advancements and economic growth, particularly in sectors like artificial intelligence, aerospace, and energy. It highlights China's new materials industry, which has surpassed 82 trillion yuan in scale, and outlines key development tasks to enhance strategic material autonomy and innovation [4][6]. Summary by Sections 1. Overview of New Materials - New materials are defined as those with superior properties or functions achieved through structural design, composition optimization, or process innovation. They encompass eleven core areas, including advanced basic materials, strategic materials, and cutting-edge materials. The new materials industry in China is projected to exceed 82 trillion yuan by 2024, with an annual growth rate of over 12% [6][5]. 2. Material Classification and Core Categories - **Advanced Basic Materials**: This includes high-strength steel, advanced non-ferrous metals, and high-performance chemical materials, which are essential for modern industrial systems and strategic emerging industries [9][11][12]. - **Strategic Materials**: High-end special materials for equipment, new generation information technology materials, and renewable energy materials are crucial for national security and technological independence [14][15][18]. - **Cutting-edge Materials**: This category includes low-dimensional materials, quantum information materials, and advanced energy materials, which are at the forefront of research and development [22][23][24]. 3. Key Development Tasks - The report outlines eight key development tasks focused on ensuring the autonomy of strategic materials, enhancing innovation capabilities, and addressing core challenges in performance breakthroughs and process barriers [4][66].

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare industry [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betaini (300957) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Details - The investment will focus on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Core Viewpoint - The company, Betaini (300957.SZ), has signed a partnership agreement with Wuxi Jinyu Mao Medical Health Industry Investment Partnership (Limited Partnership), committing to invest 50 million yuan, which will give the company a 5% stake in the fund [1] Investment Details - The investment will be managed by Jinyu Mao Investment Management Co., Ltd. [1] - The partnership primarily focuses on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]